The impact of generic substitution on price competition in Finland

European Journal of Health Economics

Volumn 9, Issue 2, 2008, Pages 185-191

  Aalto Setälä, Ville ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Generic substitution; Pharmaceutical industry; Price competition

Indexed keywords

ENALAPRIL; GENERIC DRUG; IBUPROFEN; RANITIDINE;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG SUBSTITUTION; FINLAND; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE PRICING;

COMMERCE; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; ENALAPRIL; FINLAND; IBUPROFEN; MODELS, ECONOMIC; PRESCRIPTIONS, DRUG; RANITIDINE;

EID: 42149162431     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0059-0     Document Type: Article

References (15)

1. Aronsson, T., Bergman, M.A., Rudholm, N.: The impact of generic drug competition on brand name market shares-evidence from micro data. Rev. Ind. Organ. 19(4), 425-435 (2001)
2. Berndt, E.R.: The U.S. pharmaceutical industry: why major growth in times of cost containment? Health Aff. 20(2), 100-114 (2001)
3. Boersma, C., Klok, R.M., Bos, J.M., Naunton, M., van den Berg, P.B., de Jong-van den Berg, L.T.W., Postma, M.J.: Drug costs developments after patent expiry of Enalapril, Fluoxetine and Ranitidine: a study conducted for the Netherlands. Appl. Health Econ. Health Policy 4(3), 191-196 (2005)
4. Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. US Government Printing Office, Washington (DC) (1998)
5. Dalen, D.M., Strom, S., Haabeth, T.: Price regulation and generic competition in the pharmaceutical market. Eur. J. Health Econ. 7(3), 208-214 (2006)
6. de Joncheere, K., Rietveld, A.H., Huttin, C.: Experience with generics. Int. J. Risk Saf. Med. 15, 101-109 (2002)
7. Ellison, S.F., Cockburn, I., Grilliches, Z., Hausman, J.: Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. RAND J. Econ. 28(3), 426-446 (1997)
8. Ess, S.M., Schneeweiss, S., Szucs, T.D.: European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21(2), 89-103 (2003)
9. Frank, R.G., Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econ. Manage. Strategy 6(1), 75-90 (1997)
10. Garattini, L., Ghislandi, S.: Off-patent drugs in Italy. A short-sighted view?. Eur. J. Health Econ. 7(1), 79-83 (2006)
11. Lexchin, J.: The effect of generic competition on the price of brand-name drugs. Health Policy 68(1), 47-54 (2004)
12. Paldan, M., Martikainen, J.: Lääkevaihdon ensimmäinen vuosi tilastoina. In: Riitta, A., Jaana, M. (eds.) Lääkevaihdon ensimmäinen vuosi. Social Insurance Institution, Finland (2005)
13. Poutiainen, T., Aalto-Setälä, V.: Demand for substitutable drugs. University of Helsinki, Mimeo (2006)
14. Simoens, S., De Bruyn, K., Bogaert, M., Laekeman, G.: Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23(8), 755-766 (2005)
15. Werkö, L.: The rapidly increasing cost of medicines threatens the core of healthcare. Scand. Cardiovasc. J. 38(3), 130-131 (2004)